ScinoPharm Taiwan, Ltd. Environmental Analytics
Environmental and financial analysis dashboard for ScinoPharm Taiwan, Ltd.. Industry: MANUFACTURING
Company Overview for ScinoPharm Taiwan, Ltd.
Highlights
Showing data for FY2022
Operational Environmental Cost
$4.31m
Operational Environmental Cost Intensity
4.05%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$-0.12m
Decoupling Rate (2020-2022)
-0.24%
Adjusted EBITDA
$24m
Adjusted EBITDA Margin
23%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 28.35% | 12.25% | 39.23% | ||
| 0.46% | 0.65% | 0.69% | 0.98% | |
| 3.16% | -11.58% | 12.58% | ||
| 3.57% | 4.05% | 3.37% | 3.88% | |
| $4m | $5m | $4m | $5m | |
| 6.04% | -8.29% | 17.08% | ||
| 4.04% | 4.70% | 4.05% | 4.86% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
23%
Adjusted EBIT Margin
9.61%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$110m | $100m | $106m | $104m | |
| -9.00% | 6.37% | -2.25% | ||
$82m | $75m | $77m | $77m | |
| 75.13% | 75.01% | 72.88% | 74.29% | |
$27m | $25m | $29m | $27m | |
| 24.87% | 24.99% | 27.12% | 25.71% | |
$13m | $11m | $15m | $12m | |
| 12.12% | 11.18% | 13.66% | 11.24% | |
| ENVIRONMENTAL COST DATA | ||||
$4m | $5m | $4m | $5m | |
| 4.04% | 4.70% | 4.05% | 4.86% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$23m | $20m | $24m | $22m | |
| 20.84% | 20.29% | 23.07% | 20.85% | |
$9m | $6m | $10m | $7m | |
| 8.09% | 6.48% | 9.61% | 6.38% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.69%
Scope 2 (% of Sales)
3.37%
Operational Environmental Cost Intensity
4.05%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
ScinoPharm Taiwan, Ltd. | TW | $4m | 4.05% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022